Pulmonary arterial hypertension (PAH) is a rare, progressive disorder impacting small pulmonary arteries, leading to increased vascular resistance and heart failure. The latest report forecasts ...

The disease primarily affects middle-aged women and has a poor long-term prognosis despite therapeutic advances.

There is increased risk for pulmonary hypertension in patients with both atrial fibrillation and incident venous thromboembolism.

Panelists discuss how the future of PAH treatment looks promising with potential for disease remission through reverse remodeling agents, emphasizing the need for continued research focus on patients ...

The pulmonary arterial hypertension (PAH) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, UK ...

Body weight significantly influenced right heart function and survival in pulmonary arterial hypertension, with both extremes ...

Researchers determined the presence of pulmonary hypertension was associated with worse outcomes for patients with polycythemia vera.

Long-term exposure to particulate matter in patients with pulmonary arterial hypertension increases risk for lung transplantation or death.

Endothelial dysfunction markers were linked to future disease activity and complications in lcSSc.

Results from the Phase III ZENITH trial show that patients treated with Winrevair (sotatercept-csrk) for pulmonary arterial ...

The FDA has accepted for priority review a new supplemental biologics license application for Winrevair to treat adults with ...

UBS analyst Ashwani Verma maintained a Buy rating on United Therapeutics (NASDAQ:UTHR) on June 30 but adjusted the price ...